Ohio State Navbar

Drug Shows Potential as Safe and Effective for Chronic Leukemia, Mantle Cell Lymphoma


COLUMBUS, Ohio – Two clinical studies published in the New England Journal of Medicine with an accompanying editorial suggest that the novel agent ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chronic lymphocytic leukemia (CLL) and for patients with mantle cell lymphoma (MCL).

Both studies, co-led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and at MD Anderson Cancer Center, were published in the Journal's June 19, 2013 online edition.

click here to read more